Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 24, 2024 | Onward Therapeutics transitions to the clinical stage | Onward Therapeutics licensed the exclusive worldwide rights of development, manufacture, and commercialization of OT-A201 from Biomunex Pharmaceuticals (Biomunex), a biopharmaceutical company discovering and developing bi- and multi-specif... |
| Jan 24, 2024 | Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints | EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the pha... |
| Feb 19, 2021 | Onward Therapeutics takes first steps of its buy and build strategy | Onward Therapeutics acquires licenses for potential development candidates and investing in their partners with platform technologies. The company is led by an experienced team.Grace Yeh, President and CEO of Onward Therapeutics was Founder... |
| Feb 19, 2021 | Onward Therapeutics takes first steps of its buy and build strategy |
Reviews 0
FAQ about Biomunex
What has the press written about Biomunex?
Parsers VC has collected 5 articles mentioning Biomunex, among them “Onward Therapeutics transitions to the clinical stage” (Jan 24, 2024) and “Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints” (Jan 24, 2024).
Is Biomunex still active?
Yes, Biomunex is active; its latest activity on Parsers VC dates from Oct 28, 2025.